AV650 Drug-Drug Interaction Study

Inclusion Criteria: * BMI between 18.5 to 29.9 kg/m2 * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs * Clinical laboratory evaluations within the reference range for the test laboratory * Negative test for selected drugs of abuse at Screening * Negative HBsAg and HIV antibody screens * Females of childbearing potential must be surgically sterile, post-menopausal for at least one year, or using and effective method of contraception; females of child bearing potential must have a negative serum pregnancy test at Screening and Day -1 * Males must be either sterile or agree to use an approved method of contraception * Able to comprehend and willing to sign an Informed Consent Form Exclusion Criteria: * History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, gastrointestinal, urological, neurological, psychiatric disorders, or cancer * History of inflammatory arthritis * History of symptomatic hypotension * History of severe physical injury, direct impact trauma, or neurological trauma within 6 months * History of seizure disorders * History of bipolar or major depressive disorder * History of hypersensitivity or allergies to any drug compound * Known intolerance to benzodiazepines * Known intolerance to active and/or inactive ingredients in fluvoxamine or paroxetine * History of stomach or intestinal surgery or resection, except that appendectomy, hernia repair, and/or cholecystectomy will be allowed * History or presence of an abnormal ECG * History of alcoholism, drug abuse, or drug addiction * Use of any nicotine-containing or nicotine-replacement products within 6 months of Day -1 * Participation in any other investigational study drug trial within 90 days of Day -1 * Use of any prescription medications/products within 3 months of Day 1 unless deemed acceptable by the PI * Received any vaccination or immunization within 1 month of Day -1 * Use of any over-the-counter, non-prescription preparations within 7 days of Day -1 * Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages with 72 hours of Day -1 * Poor peripheral venous access * Donation of blood within 3 months of Day -1 or of plasma within 2 weeks of Screening * Receipt of blood products within 2 months of Day 1 * Female subjects who are pregnant or nursing * Any acute or chronic condition that, in the opinion of the PI, would limit the subject's ability to complete and/or participate in this clinical study